Solid MCT Pharmaceutical Compositions for High Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for solid dosage forms of medium chain triglycerides (MCTs) with high drug loadings suitable for pharmaceutical use, as existing compositions often require MCTs to be in liquid form at room temperature, which is not desirable for all applications.
Innovation Solution
A solid pharmaceutical composition comprising a high drug loading of MCT, such as caprylic triglyceride, combined with surfactants like polyoxyl hydrogenated castor oil and a film-forming polymer like polyvinylpyrrolidone, which is self-emulsifying and spray-dried to form stable particles that convert to a stable emulsion in an aqueous environment, allowing for controlled release and increased bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MCTs are used in liquid form at room temperature, then bioavailability and solubility are improved, but ease of operation and dosage form stability deteriorate
Solution Approach 1:
The patent changes the physical state parameter of MCTs from liquid to solid through formulation with specific excipients (surfactants, co-surfactants, and other components) while maintaining the drug loading above 30% w/w. This allows the composition to be stable in solid form at room temperature yet convert to a bioavailable emulsion in the gastrointestinal tract.
Solution Approach 2:
The patent creates a composite pharmaceutical composition combining MCTs with surfactants (e.g., polyoxyl 35 hydrogenated castor oil), co-surfactants (e.g., glyceryl caprylate), and other excipients in specific ratios. This composite structure enables both solid dosage form stability and liquid-like bioavailability upon administration.
2Quantity of substance
If drug loading is increased to achieve high MCT content, then therapeutic efficacy is improved, but manufacturing precision and composition stability worsen
Solution Approach 1:
The patent optimizes the concentration parameter by establishing specific weight ratio ranges: MCTs at >30% w/w, surfactants at 5-20% w/w, and co-surfactants at 5-15% w/w. These parameter specifications enable high drug loading while maintaining composition stability through proper phase balance and emulsification characteristics.
Solution Approach 2:
The patent develops a composite system where MCTs are combined with specific ratios of surfactants and co-surfactants that stabilize the high drug loading. The synergistic interaction between these components prevents phase separation and maintains composition integrity during manufacturing and storage.
3Ease of operation
If solid dosage form is used for MCTs, then ease of operation and storage stability are improved, but solubility and emulsification capability deteriorate
Solution Approach 1:
The patent incorporates surfactants and co-surfactants in the solid dosage form that are pre-positioned to automatically activate emulsification upon contact with gastrointestinal fluids. This preliminary inclusion of emulsifying agents ensures rapid and effective emulsion formation without requiring additional processing steps.
Solution Approach 2:
The patent creates a composite material where hydrophilic surfactants and co-surfactants are integrated with the hydrophobic MCTs in the solid state. This composite structure maintains physical stability for storage while enabling spontaneous emulsification in the aqueous environment of the gastrointestinal tract.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides a stable emulsion with high bioavailability of MCTs, allowing for effective treatment of conditions associated with reduced cognitive function, such as Alzheimer’s disease, by elevating ketone body concentrations, and maintains stability and efficacy over extended periods.
Implementation Method 1
self-emulsifying and spray-dried to form stable particles that convert to a stable emulsion in an aqueous environment
Implementation Method 2
combined with surfactants like polyoxyl hydrogenated castor oil
Implementation Method 3
a film-forming polymer like polyvinylpyrrolidone
Data Source
AI summary
This invention relates to high drug load compositions of medium chain triglycerides (MCT), and to methods for treatment with such compositions at amounts effective to elevate ketone body concentrations so as to treat conditions associated with reduced neuronal metabolism, for example Alzheimer’s disease.